Pear Therapeutics, Inc. (PEAR)

NASDAQ: PEAR · IEX Real-Time Price · USD
4.33 0.14 (3.34%)
Jan 24, 2022 4:00 PM EST - Market closed
Market Cap596.67M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out137.80M
EPS (ttm)-11.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume193,321
Open4.20
Previous Close4.19
Day's Range3.77 - 4.38
52-Week Range3.77 - 14.60
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About PEAR

Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachu...

IndustryHealth Information Services
Founded2013
Employees293
Stock ExchangeNASDAQ
Ticker SymbolPEAR
Full Company Profile

Financial Performance

Financial Statements

News

Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and Reaffirms Financial and Operationa...

BOSTON--(BUSINESS WIRE)--Pear Announces Operational Performance Metrics for Full Year 2021; Reaffirms Financial and Operational Performance Metrics for Full Year 2022

1 week ago - Business Wire

Pear Therapeutics to Further Support Point32Health Members in Recovery from Substance Use Disorders

BOSTON & CANTON, Mass.--(BUSINESS WIRE)--Pear Therapeutics to Further Support Point32Health Members in Recovery from Substance Use Disorders

1 week ago - Business Wire

Pear Therapeutics closed up 25% on Monday: explained here

Shares of Pear Therapeutics Inc (NASDAQ: PEAR) closed up nearly 25% on Monday after BTIG said the Boston-headquartered company was the best positioned in the prescription digital therapeutics (PDT) spac...

3 weeks ago - Invezz

Read Why BTIG Sees An Upside OF 55% In Pear Therapeutics

BTIG initiated coverage of Pear Therapeutics Inc (NASDAQ:PEAR) with a Buy rating and $12 price target, representing an upside of almost 55%. Analyst Marie Thibault believes Pear is one of the best-posit...

3 weeks ago - Benzinga

Why Pear Therapeutics Stock Is Rising Today

Pear Therapeutics Inc (NASDAQ:PEAR) is trading higher Monday following positive analyst coverage from BTIG. BTIG analyst Marie Thibault initiated coverage on Pear Therapeutics with a Buy rating and anno...

3 weeks ago - Benzinga

Pear Therapeutics Announces the Acquisition of Two Assets Addressing a Comprehensive Spectrum of Depression Conditions

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces the Acquisition of Two Assets Addressing a Comprehensive Spectrum of Depression Conditions

1 month ago - Business Wire

Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeuti...

BOSTON--(BUSINESS WIRE)--Pear and Crossroads to Provide More Patients Access to PDTs as Standard of Care for the Treatment of Substance Use Disorders

1 month ago - Business Wire

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription D...

BOSTON--(BUSINESS WIRE)--Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company

1 month ago - Business Wire

Pear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue Guidance

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue Guidance

2 months ago - Business Wire

Thimble Point and Pear Therapeutics Announce Additional $50 Million in Committed Capital to Fund Business Plan

BOSTON--(BUSINESS WIRE)--Thimble Point and Pear Therapeutics Announce Additional $50 million in Committed Capital to Fund Business Plan

2 months ago - Business Wire

Pear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set No...

BOSTON--(BUSINESS WIRE)--Pear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement

2 months ago - Business Wire

Pear and Thimble Point Announce Nominees to Board of Directors

BOSTON--(BUSINESS WIRE)--Pear and Thimble Point Announce Nominees to Board of Directors

4 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Th...

New York, New York--(Newsfile Corp. - September 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Thimble Point Acquisition Corp. ("Th...

4 months ago - Newsfile Corp

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Thimble Point Acquisition Corp. for Potential Breac...

NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cla...

5 months ago - PRNewsWire

Digital Therapy Company Going Public Via SPAC Merger

It seems there are apps for everything—gaming, business, education, lifestyle, etc. Add to the list prescription digital therapeutics, a new class of software-based treatments.

7 months ago - GuruFocus

Pear Therapeutics Plans To Go Public In $1.6B SPAC Deal

The digital treatment developer Pear Therapeutics is taking the SPAC route to go public through a deal expected to provide about $400 million in new funding, representing a pro forma equity value of app...

7 months ago - Benzinga

Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics

7 months ago - Business Wire